Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Multiple Sclerosis
Interventions
DRUG

AVP-923

Trial Locations (20)

10003

Hospital for Joint Diseases - MS Care Center, New York

12205

Upstate Clinical Research, Albany

13210

Institute for Human Performance, Syracuse

14266

DENT Neurologic Group L.L.P., Amherst

15601

Westmorland Neurology, Greensburg

18103

Leheigh Valley Neurosciences and Pain Research Center, Allentown

19013

Neurological Associates of Delaware Valley, Upland

20037

George Washington University Medical Faculty Associates, Washington D.C.

27607

Raleigh Neurology Associates, P.A., Raleigh

30033

Neurology & Headache Specialist of Atlanta, L.L.C., Decatur

33334

Neurological Associates, Fort Lauderdale

44718

NeuroCare Center, Inc., Canton

59405

Advanced Neurology Specialists, Great Falls

60007

Radiant Research Alexian Brothers, Elk Grove Village

60062

Consultants in Neurology LTD, Northbrook

68506

Neurological Associates, P.C., Lincoln

85013

Barrow Neurological Institute, Phoenix

98122

Swedish Medical Center, Seattle

98405

Neurology and Neurosurgery Associates of Tacoma, Tacoma

05401

FACH-UHC Department of Neurological Services, Burlington

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY